Skip to main content
. Author manuscript; available in PMC: 2011 Feb 2.
Published in final edited form as: Antivir Chem Chemother. 2010 Oct 28;21(1):1–14. doi: 10.3851/IMP1680

Table 2.

Antiviral effect (EC90) of the treatment of HIV-infected MDMs with Nano-NRTIs

EC90 (AZT, μg/mL)* EC90 (ddI, μg/mL)* EC90 (AZT+ddI, μg/mL)*
AZT 3.9 ± 0.3 ddI 7.0 ± 0.4 AZT + ddI 3.6 ± 0.5
NG1/AZTTP 1.5 ± 0.4 NG1/ddITP 1.6 ± 0.3 NG1/AZTTP+ddITP 0.9 ± 0.3
AP-NG1/AZTTP 0.8 ± 0.5 AP-NG1/ddITP 1.7 ± 0.4 AP-NG1/AZTTP+ddITP 1.2 ± 0.2
NG2/AZTTP 1.5 ± 0.3 NG2/ddITP 0.6 ± 0.2
NG3/AZTTP 1.6 ± 0.3 NG3/ddITP 2.1 ± 0.5
NG4/AZTTP 1 ± 0.2 NG4/ddITP 0.5 ± 0.1
*

EC90 values (means ± SEM) were calculated from the dose-effect curves obtained for each drug/nanoformulation in three-four independent experiments